Drug
Ux111
Ux111: highest development phase Phase 2/3, developed by Ultragenyx Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| UX111 NCT02716246 | Phase 2/3 | MPS IIIA |
Latest
No recent events.
Follow Ux111 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.